

**FORM 2B  
LISTING SUMMARY**

<b>Issuer Name:</b> ORTHO REGENERATIVE TECHNOLOGIES INC.		<b>Listing Statement Date:</b> September 27, 2017	
<b>Descriptions of securities to be listed:</b> Class "A" Shares			
<b>Address:</b> 16667, Hymus Blvd. Kirkland, QC H9H 4R9		<b>Brief Description of the Issuer's Business:</b>  Ortho RTi is an emerging Orthopaedic and Sports Medicine technology company dedicated to the development of novel therapeutic tissue repair technology to dramatically improve the success rate of sports medicine surgeries for soft tissue injuries. Our proprietary biopolymer has been specifically designed to increase the healing rates of injuries to tendons, meniscus and cartilage. The polymer can be directly placed into the site of injury by a surgeon during a routine operative procedure without significantly extending the time of the surgery and without further intervention. Visit us on the internet at <a href="http://www.orthorti.com">www.orthorti.com</a> .	
<b>Company Contact:</b> Dr. Brent Norton, Executive Chairman and Acting CEO		<b>Description of securities outstanding</b>	
<b>Phone:</b> 514-782-0951		<b>Symbol</b> ORTH	<b>Type</b> Class "A" (common)
<b>Fax:</b> 514-694-0865		<b>Number</b> 18,461,500	<b>CUSIP</b> 68752F103
<b>E-mail:</b> <a href="mailto:norton@orthorti.com">norton@orthorti.com</a>		<b>If the Listing Statement was required to be filed because an event giving rise to material information has occurred that makes the previous Statement inaccurate or misleading, briefly describe the event:</b> N/A	
<b>Jurisdiction of Incorporation:</b> Canada		<b>Dates of Press Release and Any Public Filings Concerning the Event:</b> N/A	
<b>Website:</b> <a href="http://www.orthorti.com">www.orthorti.com</a>		<b>Date of Last Shareholders' Meeting and Date of Next Shareholders' Meeting (if scheduled):</b> July 19, 2017	
<b>Fiscal Year End:</b> January 31			
<b>Financial Information as at:</b> July 31, 2017		<b>Board of Directors:</b>	
<b>Current Assets</b>	\$ 674,388	<b>Name</b>	<b>Position</b>
<b>Working Capital</b>	\$ 352,505	Dr. Brent Norton	Executive Chairman and Acting CEO
<b>Total Assets</b>	\$ 1,405,621	Steve Saviuk	Director
<b>Long-Term Liabilities</b>	\$ 1,201,037	Michael Buschmann	Director, Chief Scientific Officer
<b>Shareholders' Equity (Deficiency)</b>	\$ (117,299)	Caroline Hoemann	Director
		Laurence Terisse-Rulleau	Director
		Tom ES Wright	Director